CPRX vs RYTM
CPRX: Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from established and newly approved products. RYTM: Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related neuroendocrine diseases.
Side-by-side fundamentals
| Metric | CPRX | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-07-21 close | $31.49 | $103.97 | |
| Market cap as of 2026-07-23 | $3.9B | $7.1B | |
| P/E as of 2026-07-23 | 17.42 | n/a | |
| PEG as of 2026-07-23 | 1.44 | -2.97 | RYTM lower |
| Net margin as of 2026-07-23 | +37.1% | -93.3% | CPRX higher |
| Gross margin as of 2026-07-23 | +86.0% | +89.4% | RYTM higher |
| Operating margin as of 2026-07-23 | +44.8% | -90.9% | CPRX higher |
| ROE as of 2026-07-23 | +23.6% | -86.5% | CPRX higher |
| ROA as of 2026-07-23 | +20.7% | -45.0% | CPRX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.46 | CPRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +11.7% | +58.7% | RYTM higher |
| Revenue CAGR (3y) SEC XBRL | +40.1% | +100.2% | RYTM higher |
| Beta as of 2026-07-23 | 0.78 | 1.97 | |
| 1-year return as of 2026-07-21 close | +45.7% | +18.4% | CPRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.